Studies evaluating the efficacy of 177Lu-DOTATATE
| Study | Patients, n | Location | CR/PR | PD | Time to progress, months | Median OS, months |
|---|---|---|---|---|---|---|
| Kwekkemboom et al 18 | 310 (504) | Rotterdam | 91/301 (30%) | 61/310 (20%) | 33 | 46 |
| Pencharz et al 19 | 79 | London | 10/79 (13%) | 18 (23%) | 28 | - |
| Claringbold et al (plus capecitabine) 23 | 33 | Perth | 24% | 6% | 88% at 24 months | |
| NETTER-1 study 20 | 116 | Multicentre: Europe and USA | 18% | 5% | 40 months estimate |
177Lu = Lutetium-177; CR = complete response; OS = overall survival; PD = progressive disease; PR = partial response